Biocon quest for partner in China to test generic versions of Novo Nordisk Wegovy, Ozempic

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-06-21 10:26 GMT | Update On 2024-06-21 10:26 GMT

Shanghai: Biocon is looking for a partner in China to test generic versions of Novo Nordisk's weight loss treatment Wegovy and diabetes drug Ozempic, a senior executive told Reuters.

Amit Kaptain, head of Biocon's commercial active pharmaceutical ingredients business, stated that the company aims to eventually introduce generic versions of the injectible drugs globally, and plans to find a Chinese partner for clinical trials on 500-plus patients so they can be sold in the world's second-biggest economy

"We will find it challenging to do it by ourselves because it's at least about a $12 to $15 million investment," Kaptain said, referring to a clinical trial required in China.

Biocon's CEO told Reuters earlier this year that the company was preparing to conduct a clinical trial next year if needed.

Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide, a key ingredient in both Ozempic and Wegovy, in early 2026 in China.

At least two local firms have already applied to begin commercial sales.

Read also: Biocon appoints Mukesh Kamath as Interim CFO, Key Managerial Personnel

Huge demand for Wegovy and Ozempic - which is sometimes used unofficially as a weight-loss treatment - have helped to turn Novo Nordisk into one of Europe's most valuable companies.

The number of adults who are overweight or obese in China is projected to reach 540 million and 150 million, respectively, in 2030, up 2.8 and 7.5 times from 2000 levels, according to a 2020 study, by Chinese public health researchers.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Biocon Pharma, Carnegie Pharma gain USFDA tentative nod for Rifaximin Tablets to treat irritable bowel syndrome with diarrhea

2025-10-07 05:27 GMT

Biocon quest for partner in China to test generic versions of Novo Nordisk Wegovy, Ozempic

Similar News

Wockhardt Misses NPPA Clearance for Nafithromycin, Faces Questions on Patent Validity

Zydus Gets CDSCO Panel Nod to Market Sodium Chloride Nebuliser Solution

SC doors knocked for child deaths linked to contaminated cough syrup, CBI probe demanded

AstraZeneca Pharma India bags CDSCO nod for expanded use of Trastuzumab Deruxtecan in HER2-Positive Solid Tumors

Coldrif Cough Syrup banned in Punjab amid child deaths

Contaminated cough syrup tragedy: NHRC steps in, demands investigation

DoP identifies 11,100 Jan Aushadhi Kendras across India as Outdoor Cleaning Sites

Biocon Pharma, Carnegie Pharma gain USFDA tentative nod for Rifaximin Tablets to treat irritable bowel syndrome with diarrhea